PAVmed Inc. announced a 1-for-30 reverse stock split of its common stock.
The reverse stock split will be effective on January 2, 2026, on the Nasdaq Capital Market under the symbol 'PAVM'.
This action aims to comply with the $1.00 minimum bid price requirement for its Common Stock listing on Nasdaq.
Reverse Stock Split
PAVmed will conduct a 1-for-30 reverse stock split of its Common Stock to meet Nasdaq listing requirements.
Approval
The stockholders approved the 1-for-30 reverse stock split at a special meeting on December 5, 2025.
Authorized Shares Reduction
The authorized shares of Common Stock will be reduced from 250,000,000 to 25,000,000 post reverse stock split.
- The reverse stock split will result in the reduction of available shares for equity incentive and employee stock purchase plans.
- Outstanding stock options and convertible securities will be adjusted proportionately due to the reverse stock split.
- Fractional shares of Common Stock will be rounded up to the nearest whole share to avoid incomplete ownership.
PAVmed's reverse stock split illustrates a strategic move to maintain Nasdaq listing requirements and streamline capital structure.